ReviewHepatobiliary surgery and nutrition2017
Ablative therapies for intrahepatic cholangiocarcinoma.
Review in Hepatobiliary surgery and nutrition, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer.ESMO open · 2024Guideline
- Locoregional therapy combined with systemic therapy (LRT + ST) for unresectable and metastatic intrahepatic cholangiocarcinoma: a systematic review and meta-analysis.Radiology and oncology · 2023Pooled it
- Review
- Review
- Emerging Indications for Interventional Oncology: Expert Discussion on New Locoregional Treatments.Cancers · 2023Review
- Novel Nitric Oxide Donor Dinitroazetidine-Coumarin Hybrids as Potent Anti-Intrahepatic Cholangiocarcinoma Agents.Molecules (Basel, Switzerland) · 2022Article
- Locoregional Treatments in Cholangiocarcinoma and Combined Hepatocellular Cholangiocarcinoma.Cancers · 2021Review
- Lymphoepithelioma-like cholangiocarcinoma with Epstein-Barr virus infection treated by radiofrequency ablation.Clinical journal of gastroenterology · 2021Article
- Integration of radiotherapy with anti-PD-1 antibody for the treatment of intrahepatic or hilar cholangiocarcinoma: reflection from four cases.Cancer biology & therapy · 2021Article
- The efficacy of the combination of percutaneous transhepatic biliary drainage andJournal of contemporary brachytherapy · 2020Article
- Intrahepatic cholangiocarcinoma - influence of resection margin and tumor distance to the liver capsule on survival.BMC surgery · 2020Article
- Intrahepatic Cholangiocarcinoma and Thermal Ablation: Long-term Results of An Italian Retrospective Multicenter Study.Journal of clinical and translational hepatology · 2019Article
- Ablative therapies for intrahepatic cholangiocarcinoma.Hepatobiliary surgery and nutrition · 2018Article
Corrections and comments
- Commented on by
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary hepatic malignancy. Although surgical resection has been a cornerstone in the management of ICC, the efficacies of several non-surgical management strategies have been actively investigated and somewhat preferable outcomes have been reported for ablation therapies in selected cases. Nevertheless, because of the rarity of these tumors and the small number of studies, the clinical significance and actual role of ablation therapies in a multidisciplinary approach for ICC remain unclear. In this article, the reported outcomes of ablation therapies for ICC will be summarized and their potential indications will be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.